tetano
Editor, Senior Moderator
Am J Transplant
. 2021 Apr 9.
doi: 10.1111/ajt.16599. Online ahead of print.
Changes in Humoral Immune Response after SARS-CoV-2 Infection in Liver Transplant Recipients Compared to Immunocompetent Patients
Ar?nzazu Caballero-Marcos[SUP] 1 2 [/SUP], Magdalena Salcedo[SUP] 1 2 [/SUP], Roberto Alonso-Fern?ndez[SUP] 3 [/SUP], Manuel Rodr?guez-Per?lvarez[SUP] 2 4 [/SUP], Mar?a Olmedo[SUP] 3 [/SUP], Javier Graus Morales[SUP] 5 [/SUP], Valent?n Cuervas-Mons[SUP] 6 7 [/SUP], Alba Cachero[SUP] 8 [/SUP], Carmelo Loinaz-Segurola[SUP] 9 [/SUP], Mercedes I?arrairaegui[SUP] 10 [/SUP], Llu?s Castells[SUP] 2 11 [/SUP], Sonia Pascual[SUP] 12 [/SUP], Carmen Vinaixa-Aun?s[SUP] 2 13 [/SUP], Roc?o Gonz?lez-Grande[SUP] 14 [/SUP], Alejandra Otero[SUP] 15 [/SUP], Santiago Tom?[SUP] 16 [/SUP], Javier Tejedor-Tejada[SUP] 17 [/SUP], Jos? Mar?a ?lamo-Mart?nez[SUP] 18 [/SUP], Luisa Gonz?lez-Di?guez[SUP] 19 [/SUP], Flor Nogueras-Lopez[SUP] 20 [/SUP], Gerardo Blanco-Fern?ndez[SUP] 21 [/SUP], Gema Mu?oz-Bartolo[SUP] 22 [/SUP], Francisco Javier Bustamante[SUP] 23 [/SUP], Emilio F?brega[SUP] 2 24 [/SUP], Mario Romero-Crist?bal[SUP] 1 2 [/SUP], Rosa Martin-Mateos[SUP] 5 [/SUP], Julia Del Rio-Izquierdo[SUP] 2 [/SUP], Ana Arias-Milla[SUP] 6 [/SUP], Laura Calatayud[SUP] 25 [/SUP], Alberto A Marcacuzco-Quinto[SUP] 9 [/SUP], V?ctor Fern?ndez-Alonso[SUP] 1 [/SUP], Concepci?n G?mez-Gavara[SUP] 11 [/SUP], Jordi Colmenero[SUP] 2 26 [/SUP], Patricia Mu?oz[SUP] 3 [/SUP], Jos? Antonio Pons[SUP] 27 [/SUP], Spanish Society of Liver Transplantation (SETH)
Affiliations
Abstract
The protective capacity and duration of humoral immunity after SARS-CoV-2 infection is not yet understood in solid organ transplant recipients. A prospective multicenter study was performed to evaluate the persistence of anti-nucleocapsid IgG antibodies in liver transplant recipients 6 months after coronavirus disease 2019 (COVID-19) resolution. A total of 71 liver transplant recipients were matched with 71 immunocompetent controls by a propensity score including variables with a well-known prognostic impact in COVID-19. Paired case-control serological data was also available in 62 liver transplant patients and 62 controls at month 3 after COVID-19. Liver transplant recipients showed a lower incidence of anti-nucleocapsid IgG antibodies at 3 months (77.4% vs. 100%, p<0.001) and at 6 months (63.4% vs. 90.1%, p<0.001). Lower levels of antibodies were also observed in liver transplant patients at 3 (p=0.001) and 6 months (p<0.001) after COVID-19. In transplant patients, female gender (OR=13.49, 95%CI 2.17-83.8), a longer interval since transplantation (OR=1.19, 95%CI 1.03-1.36), and therapy with renin-angiotensin-aldosterone system inhibitors (OR=7.11, 95%CI 1.47-34.50) were independently associated with persistence of antibodies beyond 6 months after COVID-19. Therefore, as compared with immunocompetent patients, liver transplant recipients show a lower prevalence of anti-SARS-CoV-2 antibodies and more pronounced antibody levels decline.
. 2021 Apr 9.
doi: 10.1111/ajt.16599. Online ahead of print.
Changes in Humoral Immune Response after SARS-CoV-2 Infection in Liver Transplant Recipients Compared to Immunocompetent Patients
Ar?nzazu Caballero-Marcos[SUP] 1 2 [/SUP], Magdalena Salcedo[SUP] 1 2 [/SUP], Roberto Alonso-Fern?ndez[SUP] 3 [/SUP], Manuel Rodr?guez-Per?lvarez[SUP] 2 4 [/SUP], Mar?a Olmedo[SUP] 3 [/SUP], Javier Graus Morales[SUP] 5 [/SUP], Valent?n Cuervas-Mons[SUP] 6 7 [/SUP], Alba Cachero[SUP] 8 [/SUP], Carmelo Loinaz-Segurola[SUP] 9 [/SUP], Mercedes I?arrairaegui[SUP] 10 [/SUP], Llu?s Castells[SUP] 2 11 [/SUP], Sonia Pascual[SUP] 12 [/SUP], Carmen Vinaixa-Aun?s[SUP] 2 13 [/SUP], Roc?o Gonz?lez-Grande[SUP] 14 [/SUP], Alejandra Otero[SUP] 15 [/SUP], Santiago Tom?[SUP] 16 [/SUP], Javier Tejedor-Tejada[SUP] 17 [/SUP], Jos? Mar?a ?lamo-Mart?nez[SUP] 18 [/SUP], Luisa Gonz?lez-Di?guez[SUP] 19 [/SUP], Flor Nogueras-Lopez[SUP] 20 [/SUP], Gerardo Blanco-Fern?ndez[SUP] 21 [/SUP], Gema Mu?oz-Bartolo[SUP] 22 [/SUP], Francisco Javier Bustamante[SUP] 23 [/SUP], Emilio F?brega[SUP] 2 24 [/SUP], Mario Romero-Crist?bal[SUP] 1 2 [/SUP], Rosa Martin-Mateos[SUP] 5 [/SUP], Julia Del Rio-Izquierdo[SUP] 2 [/SUP], Ana Arias-Milla[SUP] 6 [/SUP], Laura Calatayud[SUP] 25 [/SUP], Alberto A Marcacuzco-Quinto[SUP] 9 [/SUP], V?ctor Fern?ndez-Alonso[SUP] 1 [/SUP], Concepci?n G?mez-Gavara[SUP] 11 [/SUP], Jordi Colmenero[SUP] 2 26 [/SUP], Patricia Mu?oz[SUP] 3 [/SUP], Jos? Antonio Pons[SUP] 27 [/SUP], Spanish Society of Liver Transplantation (SETH)
Affiliations
- PMID: 33835707
- DOI: 10.1111/ajt.16599
Abstract
The protective capacity and duration of humoral immunity after SARS-CoV-2 infection is not yet understood in solid organ transplant recipients. A prospective multicenter study was performed to evaluate the persistence of anti-nucleocapsid IgG antibodies in liver transplant recipients 6 months after coronavirus disease 2019 (COVID-19) resolution. A total of 71 liver transplant recipients were matched with 71 immunocompetent controls by a propensity score including variables with a well-known prognostic impact in COVID-19. Paired case-control serological data was also available in 62 liver transplant patients and 62 controls at month 3 after COVID-19. Liver transplant recipients showed a lower incidence of anti-nucleocapsid IgG antibodies at 3 months (77.4% vs. 100%, p<0.001) and at 6 months (63.4% vs. 90.1%, p<0.001). Lower levels of antibodies were also observed in liver transplant patients at 3 (p=0.001) and 6 months (p<0.001) after COVID-19. In transplant patients, female gender (OR=13.49, 95%CI 2.17-83.8), a longer interval since transplantation (OR=1.19, 95%CI 1.03-1.36), and therapy with renin-angiotensin-aldosterone system inhibitors (OR=7.11, 95%CI 1.47-34.50) were independently associated with persistence of antibodies beyond 6 months after COVID-19. Therefore, as compared with immunocompetent patients, liver transplant recipients show a lower prevalence of anti-SARS-CoV-2 antibodies and more pronounced antibody levels decline.